Ocugen Inc
$ 1.28
3.23%
07 Aug - close price
- Market Cap 434,061,000 USD
- Current Price $ 1.28
- High / Low $ 1.30 / 1.25
- Stock P/E N/A
- Book Value 0.02
- EPS -0.26
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.68 %
- ROE -6.60 %
- 52 Week High 2.73
- 52 Week Low 0.96
About
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the development of gene therapies to cure diseases of blindness. The company is headquartered in Malvern, Pennsylvania.
Analyst Target Price
$12.17
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-07-30 | 2026-05-05 | 2026-03-04 | 2025-11-05 | 2025-08-01 | 2025-05-09 | 2025-03-05 | 2024-11-08 | 2024-08-08 | 2024-05-13 | 2024-03-26 | 2023-11-09 |
| Reported EPS | -0.07 | -0.06 | -0.06 | -0.07 | -0.05 | -0.05 | -0.05 | -0.05 | -0.04 | -0.05 | -0.03 | -0.06 |
| Estimated EPS | -0.05 | -0.05 | -0.056 | -0.06 | -0.06 | -0.06 | -0.0533 | -0.05 | -0.05 | -0.06 | -0.06 | -0.07 |
| Surprise | -0.02 | -0.01 | -0.004 | -0.01 | 0.01 | 0.01 | 0.0033 | 0 | 0.01 | 0.01 | 0.03 | 0.01 |
| Surprise Percentage | -40% | -20% | -7.1429% | -16.6667% | 16.6667% | 16.6667% | 6.1914% | 0% | 20% | 16.6667% | 50% | 14.2857% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OCGN
2026-08-08 06:40:35
Ocugen (OCGN) reported a wider-than-expected loss of 7 cents per share in Q2 2026, primarily due to increased research and development expenses, despite a slight beat on revenues which rose 8.4% to $1.5 million. The company's stock fell 3% following the announcement, reflecting an 8.2% decline year-to-date. Ocugen is advancing its ophthalmology gene therapy pipeline with multiple BLA submissions targeted by 2028, supported by recent financing that extends its cash runway into 2028.
2026-08-08 06:39:37
Wall Street Zen has downgraded Ocugen (NASDAQ:OCGN) from "Hold" to "Sell," despite a broader "Moderate Buy" consensus among analysts with a $9.50 average price target. The company recently reported a wider-than-expected quarterly loss of $0.07 per share, though revenue surpassed estimates at $1.49 million, while research and development costs significantly increased. Positive developments include FDA clearance for the Phase 3 OCU410 trial and a $130 million convertible-notes financing, which extends its cash runway but also increases debt and potential shareholder dilution.
2026-08-07 18:39:37
Ocugen reported progress across its late-stage ophthalmology pipeline in its Q2 earnings call, including FDA clearance for a Phase III study of OCU410 in geographic atrophy and an RMAT designation. The company plans to file three biologics license applications (BLAs) by 2028 and expects top-line data for OCU400 and OCU410ST in the first half of 2027. Ocugen also announced an extension of its cash runway into 2028 following a $130 million convertible notes financing.
2026-08-07 17:26:00
Ocugen Inc. (OCGN) saw its stock rise by 3.23% to $1.28 on Friday, outperforming the broader market. This increase broke a two-day losing streak for the company, occurring on a positive trading day where the S&P 500 and Dow Jones Industrial Average also posted gains.
2026-08-07 14:11:14
State Street Corporation has reported a 6.3% beneficial ownership stake in Ocugen Inc., amounting to 21,469,307 shares of common stock as of June 30, 2026. The filing, a Schedule 13G, indicates that State Street holds shared voting power over 21,055,589 shares and shared dispositive power over all 21,469,307 shares, primarily through its asset management subsidiaries. This disclosure highlights a significant passive investment by State Street in Ocugen.
2026-08-06 21:27:00
Ocugen Inc. (OCGN) stock decreased by 3.13% on Thursday, closing at $1.24. This decline occurred during a generally negative trading session where the S&P 500 Index and Dow Jones Industrial Average also fell. This marks the second consecutive day of losses for Ocugen.
